X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (12) 12
immunotherapy (9) 9
article (8) 8
cancer (8) 8
female (8) 8
oncology (8) 8
male (7) 7
animals (5) 5
asbestos (4) 4
cancer vaccines - immunology (4) 4
mesothelioma (4) 4
mice (4) 4
middle aged (4) 4
vaccination (4) 4
adult (3) 3
aged (3) 3
cancer vaccines (3) 3
immunology (3) 3
immunotherapy - methods (3) 3
lung neoplasms - genetics (3) 3
mesothelioma - genetics (3) 3
mesothelioma - pathology (3) 3
research (3) 3
t cells (3) 3
tumor suppressor proteins - genetics (3) 3
ubiquitin thiolesterase - genetics (3) 3
bap1 (2) 2
biomarkers (2) 2
biopsy (2) 2
cancer vaccines - administration & dosage (2) 2
carcinogenesis (2) 2
care and treatment (2) 2
cell proliferation (2) 2
cells (2) 2
cytotoxic t-lymphocytes (2) 2
dendritic cells (2) 2
flow cytometry (2) 2
health aspects (2) 2
hematology (2) 2
human papillomavirus (2) 2
immune response (2) 2
immune-response (2) 2
in-vivo (2) 2
interferon (2) 2
interferon-gamma - metabolism (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - immunology (2) 2
lung neoplasms - mortality (2) 2
lung neoplasms - pathology (2) 2
lymphocytes, tumor-infiltrating - immunology (2) 2
malignant mesothelioma (2) 2
malignant pleural mesothelioma (2) 2
medicine (2) 2
medicine, research & experimental (2) 2
mesothelioma - epidemiology (2) 2
mesothelioma - etiology (2) 2
mesothelioma - mortality (2) 2
mice, inbred c57bl (2) 2
mutation (2) 2
myeloid leukemia (2) 2
oncology, experimental (2) 2
papillomavirus infections - immunology (2) 2
peptides (2) 2
peptides - immunology (2) 2
pleural neoplasms - genetics (2) 2
prognosis (2) 2
prostate cancer (2) 2
prostatic neoplasms - immunology (2) 2
pulmonary and respiratory medicine (2) 2
respiratory system (2) 2
stem cells (2) 2
studies (2) 2
survival rate (2) 2
t-lymphocytes, cytotoxic - immunology (2) 2
t-lymphocytes, regulatory - immunology (2) 2
therapy (2) 2
tnfsf14 (2) 2
transformation (2) 2
tumor necrosis factor ligand superfamily member 14 - metabolism (2) 2
tumor-suppressor (2) 2
tumors (2) 2
virus-like particles (2) 2
6-transmembrane epithelial antigen (1) 1
abl genomic rearrangement (1) 1
adenocarcinoma (1) 1
adenovirus (1) 1
adenoviruses (1) 1
adhesion (1) 1
adjuvant (1) 1
aged, 80 and over (1) 1
air pollutants - adverse effects (1) 1
air sampling (1) 1
alleles (1) 1
allergy and immunology (1) 1
alpha therapy (1) 1
amino acids (1) 1
anal intraepithelial neoplasia (1) 1
analysis (1) 1
anergy (1) 1
animal models (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current Cancer Drug Targets, ISSN 1568-0096, 02/2007, Volume 7, Issue 1, pp. 79 - 89
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2011, Volume 108, Issue 33, pp. 13618 - 13623
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 04/2015, Volume 10, Issue 4, pp. 565 - 576
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 2010, Volume 5, Issue 7, p. e11770
Background: Interferon-alpha (IFN) induces complete cytogenetic remission (CCR) in 20-25% CML patients and in a small minority of patients; CCR persists after... 
CD34(+) CELLS | IN-VITRO | STEM-CELLS | DENDRITIC CELLS | ALPHA THERAPY | BIOLOGY | ABL GENOMIC REARRANGEMENT | SERINE-PROTEASE | IMATINIB MESYLATE | CHRONIC MYELOID-LEUKEMIA | LYMPHOCYTES | T-Lymphocytes, Cytotoxic - immunology | Peptides - chemistry | Humans | Middle Aged | Peptides - immunology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Interferon-gamma - metabolism | Remission Induction | Interferon-alpha - administration & dosage | Interferon-alpha - urine | Flow Cytometry | Peptides - chemical synthesis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Adult | Female | Cytogenetic Analysis | HLA-A2 Antigen - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Histocompatibility antigens | Peptides | Immunotherapy | HLA histocompatibility antigens | Interferon | B cells | Biological response modifiers | T cells | CD57 antigen | Cell proliferation | CC chemokine receptors | Transplants & implants | Anergy | Leukemia | CD45RA antigen | Proteinase | Cytotoxicity | Lymphocytes T | Kinases | CD28 antigen | Cancer therapies | Immunity | Cell growth | Immunology | Lymphocytes | Peripheral blood | Remission | Elastase | Protein-tyrosine kinase | Tyrosine | Antigens | Immunological memory | Memory cells | Imatinib | Cytokines | Dendritic cells | Myeloid leukemia | CCR7 protein | T cell receptors | Chronic myeloid leukemia | Patients | Studies | γ-Interferon | Stem cells | Histocompatibility antigen HLA | Proteinase 3
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 08/2016, Volume 11, Issue 8, pp. 1246 - 1262
Journal Article
The Prostate, ISSN 0270-4137, 02/2015, Volume 75, Issue 3, pp. 280 - 291
Journal Article
Leukemia, ISSN 0887-6924, 03/2017, Volume 31, Issue 3, pp. 697 - 704
PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes... 
CHRONIC MYELOGENOUS LEUKEMIA | TRIAL | REGRESSION | INTERFERON | THERAPY | CELL RESPONSES | ONCOLOGY | WT1 | PROTEINASE-3 | HEMATOLOGY | CYTOTOXIC T-LYMPHOCYTES | MYELODYSPLASTIC SYNDROMES | T-Lymphocyte Subsets - immunology | Leukocytes, Mononuclear - metabolism | Humans | Vaccination | Male | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Leukemia, Myeloid, Acute - immunology | Peptides - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Leukocytes, Mononuclear - immunology | Female | Epitopes, T-Lymphocyte - immunology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myeloid, Acute - therapy | HLA-A2 Antigen - immunology | Cancer Vaccines - administration & dosage | Peptides - immunology | Cancer Vaccines - adverse effects | Immunophenotyping | Treatment Outcome | HLA-A2 Antigen - chemistry | Leukemia, Myeloid, Acute - mortality | Cancer Vaccines - immunology | Leukemia, Myeloid, Acute - diagnosis | T-Lymphocyte Subsets - metabolism | Survival Analysis | Biomarkers | T-Cell Antigen Receptor Specificity | Immunologic Memory | Peptides - adverse effects | Cancer vaccines | Care and treatment | Patient outcomes | Immunotherapy | Oncology, Experimental | Research | Myelodysplastic syndromes | Cancer | Vaccine | CTL | Immune Response | PR1 | Myeloid Leukemia
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2012, Volume 18, Issue 19, pp. 5352 - 5363
Journal Article